- Home
- SAN vs GILD Comparison
SAN vs GILD Comparison
Compare SAN & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAN | GILD |
|---|---|---|
| Founded | 1857 | 1987 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.8B | 187.5B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | SAN | GILD |
|---|---|---|
| Price | $13.11 | $145.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 18 |
| Target Price | N/A | ★ $143.50 |
| AVG Volume (30 Days) | ★ 15.8M | 6.8M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | 1.40% | ★ 2.23% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | N/A | ★ 6.78 |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | $24.67 | $4.68 |
| Revenue Next Year | $5.22 | $5.81 |
| P/E Ratio | ★ $11.21 | $21.70 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $5.54 | $95.30 |
| 52 Week High | $13.24 | $157.29 |
Technical Indicators
Market Signals| Indicator | SAN | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 58.59 | 50.23 |
| Support Level | $11.82 | $108.90 |
| Resistance Level | $13.11 | $157.29 |
| Average True Range (ATR) | 0.29 | 4.02 |
| MACD | 0.04 | -1.61 |
| Stochastic Oscillator | 89.67 | 5.40 |
Price Performance
Historical ComparisonAbout SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).